{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:20:27Z","timestamp":1775830827313,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute bacterial prostatitis (ABP) is a complicated urinary tract infection (UTI) requiring timely and appropriate antibiotic therapy. Because of growing concern over fluoroquinolone resistance, second-generation cephalosporins such as cefuroxime may offer a viable alternative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluates the use of cefuroxime as an empirical first-line intravenous treatment in hospitalized patients with ABP and compares outcomes following various oral antibiotic step-down regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-centre retrospective cohort study at Clinique Saint-Pierre Ottignies, Belgium, including male patients \u226518 years diagnosed with ABP and treated empirically with intravenous cefuroxime between January 2019 and December 2023. Patients were grouped based on their oral antibiotic step-down therapy (cefuroxime, ciprofloxacin, trimethoprim\u2013sulfamethoxazole or amoxicillin). The primary outcomes were bacterial failure and clinical recurrence within 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 148 patients screened, 88 met inclusion criteria. No relapses were reported. Escherichia coli was the predominant pathogen (49\/88); 100% were cefuroxime-susceptible, while four were fluoroquinolone-resistant. Among non-E. coli isolates, resistance to cefuroxime was significantly higher (OR 8.5, P\u200a=\u200a0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Empirical intravenous cefuroxime followed by oral step-down appears safe and effective for ABP, especially in the absence of known risk factors for resistant pathogens. These findings support fluoroquinolone-sparing approaches in empiric UTI management, tailored to local microbiological profiles and individual comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf250","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:06:53Z","timestamp":1766063213000},"source":"Crossref","is-referenced-by-count":1,"title":["Prioritizing cefuroxime as empirical treatment in acute bacterial prostatitis: patient characteristics and outcome"],"prefix":"10.1093","volume":"8","author":[{"given":"Emilien","family":"Lecomte","sequence":"first","affiliation":[{"name":"Service of Internal Medicine, Clinique Saint-Pierre , Ottignies ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Arys","sequence":"additional","affiliation":[{"name":"Service of Internal Medicine, Clinique Saint-Pierre , Ottignies ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Christiaens","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, Universit\u00e9 Catholique de Louvain , Brussels ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Doyen","sequence":"additional","affiliation":[{"name":"Service of Internal Medicine, Clinique Saint-Pierre , Ottignies ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Marot","sequence":"additional","affiliation":[{"name":"Service of Internal Medicine, Clinique Saint-Pierre , Ottignies ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Verbelen","sequence":"additional","affiliation":[{"name":"Service of Microbiology, Clinique Saint Pierre , Ottignies ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Wie\u00ebrs","sequence":"additional","affiliation":[{"name":"Service of Internal Medicine, Clinique Saint-Pierre , Ottignies ,","place":["Belgium"]},{"name":"Department of Medicine, Faculty of Medicine, Namur Research Institute for Life Sciences (NARILIS), University of Namur , Namur ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2026012903413432700_dlaf250-B1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jama.282.3.236","article-title":"NIH consensus definition and classification of prostatitis","volume":"282","author":"Krieger","year":"1999","journal-title":"JAMA"},{"key":"2026012903413432700_dlaf250-B2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0022-5347(18)34367-2","article-title":"Are urinary tract infections associated with prostatitis symptoms: results from the Boston area community health (BACH) survey","volume":"173","author":"Daniels","year":"2005","journal-title":"J Urol"},{"key":"2026012903413432700_dlaf250-B3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-59745-472-8_2","volume-title":"Chronic Prostatitis\/Chronic Pelvic Pain Syndrome","author":"Naber","year":"2008"},{"key":"2026012903413432700_dlaf250-B4","doi-asserted-by":"publisher","first-page":"e0274194","DOI":"10.1371\/journal.pone.0274194","article-title":"A retrospective review of oral cephalosporins versus fluoroquinolones for the treatment of pyelonephritis","volume":"17","author":"Lin","year":"2022","journal-title":"PLoS One"},{"key":"2026012903413432700_dlaf250-B5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jhin.2004.07.016","article-title":"Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit","volume":"59","author":"Aubert","year":"2005","journal-title":"J Hosp Infect"},{"key":"2026012903413432700_dlaf250-B6","doi-asserted-by":"publisher","first-page":"ofab070","DOI":"10.1093\/ofid\/ofab070","article-title":"The effect of antibiotic restriction programs on prevalence of antimicrobial resistance: a systematic review and meta-analysis","volume":"8","author":"Schuts","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026012903413432700_dlaf250-B7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dkt422","article-title":"Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle","volume":"69","author":"De Lastours","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026012903413432700_dlaf250-B8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.amjmed.2008.04.039","article-title":"Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates","volume":"121","author":"Johnson","year":"2008","journal-title":"Am J Med"},{"key":"2026012903413432700_dlaf250-B9","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.japh.2023.06.028","article-title":"Cephalosporins for the treatment of uncomplicated pyelonephritis: a systematic review","volume":"63","author":"Zimmerman","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"2026012903413432700_dlaf250-B10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/00003495-199652010-00009","article-title":"Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy","volume":"52","author":"Perry","year":"1996","journal-title":"Drugs"},{"key":"2026012903413432700_dlaf250-B11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cmi.2022.05.035","article-title":"How I manage bacterial prostatitis","volume":"29","author":"Lam","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026012903413432700_dlaf250-B12","author":"Bonkat"},{"key":"2026012903413432700_dlaf250-B13","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S0140-6736(24)01885-3","article-title":"Global burden of antimicrobial resistance and forecasts to 2050","volume":"404","author":"Kariuki","year":"2024","journal-title":"Lancet"},{"key":"2026012903413432700_dlaf250-B14","doi-asserted-by":"publisher","first-page":"dlae071","DOI":"10.1093\/jacamr\/dlae071","article-title":"Intravenous cefuroxime as a first-line treatment for women hospitalized for pyelonephritis","volume":"6","author":"Everard","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026012903413432700_dlaf250-B15","doi-asserted-by":"publisher","first-page":"e0047923","DOI":"10.1128\/msphere.00479-23","article-title":"The impact of three carbapenems at a single-day dose on intestinal colonization resistance against carbapenem-resistant Klebsiella pneumoniae","volume":"8","author":"Kuang","year":"2023","journal-title":"mSphere"},{"key":"2026012903413432700_dlaf250-B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1128\/AAC.00851-06","article-title":"Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance","volume":"5","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012903413432700_dlaf250-B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13613-017-0296-z","article-title":"Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration","volume":"7","author":"Yusuf","year":"2017","journal-title":"Ann Intensive Care"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlaf250\/66290174\/dlaf250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlaf250\/66290174\/dlaf250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:41:37Z","timestamp":1769676097000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf250\/8416244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf250","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,7]]},"article-number":"dlaf250"}}